By observing in our clinical practice that almost half of the patients had a negative genetic result despite the biochemical suspicion of FHH, we pursued a comparative evaluation of clinical, biochemical, imaging and therapeutic strategies between FHH-negative and FHH-positive cases to better refine the identification of those individuals who might have a positive genetic evaluation. The gene discussed is CASR; the disease is familial hypocalciuric hypercalcemia.